Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

• HLA-A*02:01-positive

• Histologically confirmed advanced colorectal, esophageal, gastric, or ovariancarcinoma

• Archived or fresh tumor tissue sample that must be confirmed as adequate

• Evaluable/Measurable disease per RECIST 1.1

• Previously received applicable standard treatments

• Male and female participants of childbearing potential who are sexually active witha non-sterilized partner must agree to use highly effective methods of birth control

Exclusion Criteria:

• Symptomatic or untreated central nervous system metastasis

• Recent bowel obstruction

• Ongoing ascites or effusion requiring recent drainages

• Significant ongoing toxicity from prior anticancer treatment

• Out-of-range laboratory values

• Clinically significant lung, heart, or autoimmune disease

• Ongoing requirement for immunosuppressive treatment

• Significant secondary malignancy

• Hypersensitivity to study drug or excipients

• Pregnant or lactating